
Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO
pharmafile | April 21, 2026 | Appointment | | Remedy Plan Therapeutics
Remedy Plan Therapeutics has appointed Jotin Marango as Chief Financial and Business Officer (CFO & CBO).
“Joti brings a strong blend of corporate leadership, financial insight, strategic creativity, and all- around deep experience in the biotechnology sector,” said Greg Crimmins, Founder and CEO of Remedy Plan Therapeutics.
Marango brings more than 15 years of experience across biotechnology, business development, corporate strategy, and public markets. He most recently served as Chief Operating Officer and Chief Financial Officer at Ikena Oncology, a company focused on small molecule design and development across solid tumor oncology, where he was instrumental in capital raising and allocation, business partnerships, and strategic transactions, including Ikena’s merger with ImageneBio.
Previously, Marango served as CFO and CBO at Aptose Biosciences, a company focused on the early clinical development of multiple small molecules across acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Earlier in his career, Marango worked as an equity research analyst covering small and mid-cap biotechnology companies focused on haematology, oncology, and rare diseases.
Remedy Plan Therapeutics is a clinical-stage biotechnology company developing novel therapies that target fundamental metabolic vulnerabilities in disease.






